Radius Recycling Inc Stock Price, News & Analysis

Radius Health has acquired global development rights to RAD011, a synthetic cannabidiol oral solution, for $12.5 million, with up to $60 million in milestone payments. The drug targets Prader-Willi syndrome (PWS), an orphan disease, and has received Orphan Drug and Fast Track Designation from the FDA. The acquisition will be funded through existing operations, minimizing shareholder dilution. Radius expects to initiate a pivotal Phase 2/3 study for PWS in late 2021, with potential top-line data available by 2023. A one-time charge of up to $16 million is expected in Q4 2020 due to the acquisition.

On January 5, 2021, Endo International plc (NASDAQ: ENDP) announced a licensing agreement with Radius Health, Inc. (NASDAQ: RDUS) for the exclusive commercialization of abaloparatide in Canada, through its subsidiary Paladin Labs Inc. Abaloparatide is an investigational treatment for osteoporosis, with Paladin expected to file a New Drug Submission with Health Canada by Q1 2022. The drug is not yet approved in Canada, but Endo aims to address a significant treatment gap for osteoporosis patients.

Radius Health has formed an agreement with Endo Ventures to commercialize and distribute abaloparatide in Canada. This partnership includes an upfront payment and milestone payments totaling around $8 million, plus tiered royalties on net sales. Paladin Labs will manage all commercial activities, targeting a New Drug Submission to Health Canada for TYMLOS® by early 2022. The initiative marks a strategic effort to expand abaloparatide's presence in select ex-U.S. markets, reflecting Radius's commitment to growth in 2021.

Radius Health, Inc. (Nasdaq: RDUS) has appointed Machelle Sanders and Dr. Andrew C. von Eschenbach to its board of directors, filling vacancies left by Jessica Hopfield, Ph.D. and Tony Rosenberg. Sanders brings over 25 years of pharmaceutical experience, having previously led Biogen's operations for its MS franchise. Dr. von Eschenbach, a former FDA commissioner, adds significant expertise in translating science into therapeutics. Chairman Owen Hughes expressed confidence in their contributions to Radius's emerging pipeline as the company refines its focus.

Radius Health, Inc. (Nasdaq: RDUS) reported continued growth in net new patients for TYMLOS-SC, with 1,326 new patients added in November 2020, marking an 8.0% increase from the previous average. The company is on track for a record quarter in TYMLOS-SC net revenue, surpassing the previous high of $56.7 million from Q4 2019. Additionally, Radius formed a research agreement with Massachusetts General Hospital to explore small molecules for musculoskeletal diseases. Peter Butler, MD, has been appointed as Head of Clinical Development for the abaloparatide program.

Radius Health (RDUS) reported Q3 2020 net sales of TYMLOS at $50.4 million, marking an 8% year-over-year increase. The total revenue for the quarter reached $77.8 million, supported by a significant rise in net new U.S. patients, increasing by 10% in October. The company maintains a cash balance of $126 million, ensuring operational funding for at least a year. However, Radius faced a net loss of $6.3 million for the quarter, though an improvement compared to last year's loss of $30 million. Japan's market launch of abaloparatide injection is on track for 2021.

Radius Health, Inc. (RDUS) announced significant clinical and business developments. Key highlights include the completion of enrollment in three pivotal Phase III clinical trials for osteoporosis treatments and a successful data presentation at the ASBMR meeting. The company also completed two business transactions, focusing on its oncology assets and repositioning its commercial strategy towards high-risk fracture patients. Additionally, operational improvements resulted in reduced sales territories and increased operational efficiency.

Radius Health (Nasdaq: RDUS) announced the release of its third quarter financial results on November 5, 2020, with a conference call scheduled at 8:30 a.m. ET. Investors can access the call via domestic and international dial-in numbers, with a replay available later the same day. Radius focuses on developing innovative endocrine therapeutics, including its FDA-approved product, TYMLOS, for postmenopausal women with osteoporosis. The company's pipeline includes investigational treatments for osteoporosis in men and hormone-receptor positive breast cancer.

Radius Health, Inc. (Nasdaq: RDUS) has appointed Peter A. Schwartzman as Vice President of the newly created Capital, Strategy, and Transactions (CST) Group. Schwartzman previously worked at Piney Lake Capital Management and has extensive experience in healthcare investments. The CST group will handle business development analysis, due diligence, and serve as a contact point for capital providers and investment banks. This strategic move aims to enhance Radius's financial modeling and business opportunities.